@article {Muller:1 August 2005:1472-8222:831,
	author = "Muller, Alexander J",
	author = "Malachowski, William P",
	author = "Prendergast, George C",
	title = "Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors",
	journal = "Expert Opinion on Therapeutic Targets",
	volume = "9",
	year = "1 August 2005",
	abstract = "Indoleamine 2,3-dioxygenase (IDO) is an interferon (IFN)-<IMG SRC="/iso-ents/isogrk32/gamma-s.gif" ALT="gamma">-inducible, extrahepatic enzyme that catalyses the initial and rate-limiting step in the degradation of the essential amino acid tryptophan. Elevated tryptophan catabolism mediated by IDO is associated with a wide variety of human cancers and has historically been thought to be a tumoricidal consequence of IFN-<IMG SRC="/iso-ents/isogrk32/gamma-s.gif" ALT="gamma"> exposure. Evidence of a physiological requirement for IDO activity in protecting the allogeneic fetus from rejection by the maternal immune system has stimulated a radical shift in thinking about the role of IDO in cancer. Evidence now suggests that tumours can exploit IDO-mediated peripheral tolerance to promote immune escape. This review summarises key studies that implicate IDO as an important mediator of peripheral immune tolerance as well as the development of a promising new anticancer modality that incorporates the use of IDO inhibitors. The second part focuses on the current state of development of IDO inhibitory compounds as potential phar-maceutical agents.",
	pages = "831-849(19)",
	url = "http://www.ingentaconnect.com/content/apl/ett/2005/00000009/00000004/art00012"
	doi = "doi:10.1517/14728222.9.4.831"
}